CorMedix Inc
NASDAQ:CRMD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.86
16.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
CorMedix Inc
Revenue
CorMedix Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
CorMedix Inc
NASDAQ:CRMD
|
Revenue
$214.3m
|
CAGR 3-Years
1 189%
|
CAGR 5-Years
304%
|
CAGR 10-Years
95%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$92.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$64.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$59.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
What is CorMedix Inc's Revenue?
Revenue
214.3m
USD
Based on the financial report for Sep 30, 2025, CorMedix Inc's Revenue amounts to 214.3m USD.
What is CorMedix Inc's Revenue growth rate?
Revenue CAGR 10Y
95%
Over the last year, the Revenue growth was 1 648%. The average annual Revenue growth rates for CorMedix Inc have been 1 189% over the past three years , 304% over the past five years , and 95% over the past ten years .